Metastatic Liver Cancer - Pipeline Review, Q3 2011

Metastatic Liver Cancer - Pipeline Review, Q3 2011

Summary

Global Markets Direct’s, 'Metastatic Liver Cancer - Pipeline Review, Q3 2011', provides an overview of the Metastatic Liver Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Liver Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer. 'Metastatic Liver Cancer - Pipeline Review, Q3 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Metastatic Liver Cancer.
- A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Metastatic Liver Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Metastatic Liver Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Metastatic Liver Cancer pipeline depth and focus of Metastatic Liver Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Metastatic Liver Cancer Overview
Therapeutics Development
Metastatic Liver Cancer Therapeutics under Development by Companies
Metastatic Liver Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Mid Clinical Stage Products
Early Clinical Stage Products
Pre-Clinical Stage Products
Metastatic Liver Cancer Therapeutics - Products under Development by Companies
Metastatic Liver Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Metastatic Liver Cancer Therapeutics Development
Metastatic Liver Cancer - Therapeutics Assessment
Late Stage Drug Profiles
Metastatic Liver Cancer Therapeutics – Drug Profile Updates
Metastatic Liver Cancer Therapeutics - Discontinued Products
Appendix
Methodology
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Metastatic Liver Cancer, Q3 2011
Products under Development for Metastatic Liver Cancer – Comparative Analysis, Q3 2011
Number of Products under Development by Companies, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Number of Products under Investigation by Universities/Institutes, Q3 2011
Comparative Analysis by Late Stage Development, Q3 2011
Comparative Analysis by Mid Clinical Stage Development, Q3 2011
Comparative Analysis by Early Clinical Stage Development, Q3 2011
Comparative Analysis by Pre-Clinical Stage Development, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
F. Hoffmann-La Roche Ltd., 2011
Biogen Idec Inc., 2011
Light Sciences Oncology, Inc., 2011
Sirtex Medical Limited, 2011
RXi Pharmaceuticals Corporation, 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Metastatic Liver Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Metastatic Liver Cancer, Q3 2011
Products under Development for Metastatic Liver Cancer – Comparative Analysis, Q3 2011
Products under Development by Companies, Q3 2011
Products under Investigation by Universities/Institutes, Q3 2011
Late Stage Products, Q3 2011
Mid Clinical Stage Products, Q3 2011
Early Clinical Stage Products, Q3 2011
Pre-Clinical Stage Products, Q3 2011
Assessment by Monotherapy Products, Q3 2011
Assessment by Combination Products, Q3 2011
Assessment by Route of Administration, Q3 2011
Assessment by Stage and Route of Administration, Q3 2011
Assessment by Molecule Type, Q3 2011
Assessment by Stage and Molecule Type, Q3 2011